Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nivolumab+ Plinabulin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nivolumab + Plinabulin | EXPERIMENTAL | Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression |
| Name | Type | Description |
|---|---|---|
| Nivolumab + Plinabulin | DRUG | - |
Inclusion Criteria: * Subjects with histologically or cytologically-confirmed metastatic NSCLC whose disease progressed during/after treatment with at least one platinum-containing chemotherapy regimen. * At least 1 prior systemic therapy for metastatic disease. Adjuvant chemotherapy or concurrent ...
Top 20 of 84 competitors
Nivolumab is used for Non-small Cell Lung Cancer Metastatic and Lung Cancer. It is being studied in combination with other agents. In a completed Phase 1 trial, Nivolumab was combined with Plinabulin in patients with metastatic Non-small Cell Lung Cancer. The trial enrolled 18 participants in the United States.
Nivolumab is developed by BeyondSpring, Inc., a company traded under the ticker BYSI. The drug is being investigated in oncology, specifically for Non-small Cell Lung Cancer Metastatic and Lung Cancer. BeyondSpring is conducting clinical trials to evaluate Nivolumab in combination with other therapies.
Nivolumab is in Phase 1 clinical development. It is an investigational drug, not yet approved. Two Phase 1 trials have been completed, one in metastatic Non-small Cell Lung Cancer and another in recurrent Small Cell Lung Cancer. Both trials were conducted in the United States.
Nivolumab has been studied in two completed Phase 1 trials. NCT02812667 evaluated Nivolumab with Plinabulin in metastatic Non-small Cell Lung Cancer, enrolling 18 patients. NCT03575793 studied Nivolumab, Ipilimumab, and Plinabulin in recurrent Small Cell Lung Cancer, enrolling 39 patients. Both trials were in the United States.
No, Nivolumab is not the same as Plinabulin. Nivolumab is the drug being developed by BeyondSpring, Inc. Plinabulin is a separate agent used in combination with Nivolumab in clinical trials. The trials combine Nivolumab with Plinabulin, sometimes with Ipilimumab, to treat lung cancers.